The spigot of venture capital funding and investments pouring into life sciences and biotech, which have supercharged the sector and the development of lab space, hit record levels last year — but experts expect the growth to slow down this year amid the broader dip in the markets. Venture capital funding for startups hit a record $43.3B last year, according to Newmark’s just-published year-end analysis, topping the record $29.9B haul from 2020. That represents a compound annual growth rate of roughly 21.3% over the last decade, an indication of the industry’s stratospheric growth and a symbol of robust future demand for lab developers. 
“If you’re raising money, you want to target something with secular growth possibility,” Newmark Associate Director of Capital Market Research Daniel Littman, author of the report, told Bisnow. “Something that’ll grow beyond economic cycles and regular ups and downs. These have been record fundraising years, with a record amount of…  Read the full story here. | 
